Publicaciones en colaboración con investigadores/as de University of Bonn (7)

2024

  1. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2

    Ophthalmology, Vol. 131, Núm. 8, pp. 914-926

2022

  1. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

    The Lancet, Vol. 399, Núm. 10326, pp. 729-740

2020

  1. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

    Acta Neuropathologica

2018

  1. Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: Chroma and spectri phase 3 randomized clinical trials

    JAMA Ophthalmology, Vol. 136, Núm. 6, pp. 666-677

2017

  1. Vitamin D and age-related macular degeneration

    Nutrients, Vol. 9, Núm. 10

2016

  1. Omega-3 Fatty Acids and Age-Related Macular Degeneration

    Ophthalmic Research, Vol. 55, Núm. 2, pp. 62-69

2013

  1. Micronutrients in age-related macular degeneration

    Ophthalmologica, Vol. 229, Núm. 2, pp. 75-79